United Therapeutics Chairperson & CEO Executes 10b5-1 Option Exercise & Sale

Executive Summary

On September 1, 2026, Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corp ($UTHR), exercised stock options to acquire 9,500 shares of common stock at $135.42 per share and subsequently sold all 9,500 shares across multiple weighted average price tranches ranging from $510.72 to $516.62 per share. The aggregate disposition value totaled approximately $4.88 million.

Transaction Details

• Option Exercise: 9,500 options exercised at $135.42 per share (exercised under family trust ownership).
• Sale Breakdown: 9,500 shares were sold indirectly via trust across multiple executions between $510.43 and $516.57, averaging roughly $514.09 per share.
• Plan Details: The transactions were conducted pursuant to a pre-arranged Rule 10b5-1 trading plan established on November 7, 2025.

Post-Transaction Holdings

Following these transactions, Dr. Rothblatt continues to hold substantial direct and indirect equity:

• 324,443 shares held indirectly via the transacting trust
• 40,513 shares held directly
• Over 303,000 additional shares held across various family trusts and spouse holdings
• 18,410 remaining options in the transacting trust

Market & Governance Context

Because this transaction represents a routine exercise-and-sell program under an established Rule 10b5-1 plan, it indicates standard programmatic liquidity and estate planning rather than a discretionary signal on company fundamentals.